Get the full Gynger company profile
Access contacts, investors, buying signals & more
For B2B technology vendors navigating the complexities of accounts receivable, Gynger has secured a fresh $20.0M in Series A funding. The embedded financing solution aims to give these vendors the power to offer flexible payment terms to customers while still securing upfront payment.
This new capital will support Gynger's platform, which is designed to help finance leaders optimize day-to-day cash flows, accelerate deal flows, and execute long-term strategic vision with greater ease.
AltExchange
AltExchange is now part of iCapital.
$3.0M Seed
today
Clicklease
Clicklease is the payment solution that says “yes.” Our innovative payment solution connects equipment vendors with small businesses through flexible, affordable payment plans. The solution’s proprietary algorithm doesn’t need to consider FICO scores for approval, empowering customers who can’t get funding otherwise. Business owners simply shop for the equipment they need on their favorite vendor websites, click to apply for Clicklease payments, complete the 4-minute application, receive instant approval, and enjoy same-day funding. Our solution is a win-win. It not only helps small businesses buy what they need to succeed, it helps equipment vendors sell what they need to grow. And when businesses grow, so do families, communities, and economies.
$220.0M Unknown
today
Parabilis Medicines
Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact.
$670.0M Unknown
today
Hybar
A technologically advanced, environmentally sustainable scrap metal recycling steel rebar mill in Osceola, Arkansas.
$1.1B Unknown
today
Able Made
Sustainable athleisure for the active and the activists, powering a global movement that unites us for the love of the game, the planet and each other.
$2.0M Seed
today
Largest funding rounds in FinTech on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Access Bank Plc Nigeria | Unknown | $100.0B | 1y ago |
| 2 |  Klarna Sweden | Unknown | $45.6B | 1y ago |
| 3 |  NatWest Group United Kingdom | Unknown | £23.4B | 1y ago |
| 4 |  Finitt by Fintranxect India | Series a | $7.0B | 1y ago |
| 5 |  Groww India | Seed | $5.8B | 7mo ago |
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Mako Networks United States | Series a | $28.0M | today |
| 2 |  Obol United States | Series a | $15.0M | today |
| 3 |  Sopht I B Corp certified France | Series a | $5.5M | today |
| 4 |  Telum Therapeutics Spain | Series a | $18.0M | today |
| 5 |  Beeline Medicines United States | Series a | $126.3M | 1d ago |
